Novartis presents positive data for Cosentyx in skin disorder HS

Novartis says that Cosentyx provided rapid relief to patients in two phase 3 trials against the debilitating skin condition hidradenitis ...

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis ...

The data showed that treatment response rates in patients randomized to Cosentyx continued to improve beyond the primary endpoint analysis at ...

Novartis Cosentyx® shows clinically meaningful symptom ...

Available data support the sustained efficacy over continuous treatment up to 52 weeks in patients with HS7. “We are excited to share these ...

Novartis' Cosentyx eases symptoms in hidradenitis suppurativa trials

Novartis has reported data from two Phase III clinical trials where its Cosentyx (secukinumab) offered quick and lasting relief from moderate-to-severe ...

Patients with hidradenitis suppurativa experienced sustained ...

“These data show that Cosentyx could provide meaningful and long-lasting improvement of HS symptoms. Based on these encouraging data, we hope to ...

Patients With Hidradenitis Suppurativa Treated With Novartis ...

Long-term data from the pivotal SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) clinical trials, which evaluated secukinumab (Cosentyx) ...

Novartis presents positive Phase III results for Cosentyx® in children ...

Treatment with Cosentyx (secukinumab) resulted in a 72% reduced flare risk versus placebo, with improvement in disease activity over two years across both ...

Secukinumab in patients with moderate-to-severe hidradenitis ...

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with a substantial disease burden. Secukinumab has previously been reported to ...

Novartis shines a light on HS at the Tribeca Festival - Fierce Pharma

Novartis released 52-week data for Cosentyx in HS. The drug's response rate—as measured by inflammatory lesion and skin abscesses on a marker ...

Positive Results from 2 Novartis Trials for HS Treatment

Both trials, SUNSHINE and SUNRISE, contained positive results of the efficacy of secukinumab vs placebo with statistically significant improvement in HS signs ...

Cosentyx Mar2023.SIN - Novartis

As a direct consequence treatment with secukinumab reduces erythema, induration, and desquamation present in plaque psoriasis lesions. ... Pooled data (HS study 1 ...

Cosentyx® (secukinumab) receives expanded approvals in EU for ...

“Cosentyx could now provide a treatment option for eligible patients who continue to struggle with the painful symptoms which negatively impact ...

HS Treatment Response Rates Continue to Improve with ...

Newly released safety and efficacy data on Novartis' secukinumab for hidradenitis suppurativa is published in The Lancet. Advertisement. In two ...

Cosentyx, INN-secukinumab - European Medicines Agency

... data) experienced a clinically relevant decrease in HS-related skin pain ... Cosentyx is used to treat a condition called hidradenitis suppurativa ...

Novartis Cosentyx® receives FDA approval for the treatment of ...

Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis.

Patients with hidradenitis suppurativa experienced sustained ...

• HS is a recurrent skin disease affecting one in ... additional promising data about the long-term efficacy and safety of Cosentyx in HS.

FDA Approves Novartis Cosentyx® as the First New Biologic ...

FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa ...

News Archive | Novartis United States of America

October 2023 · FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade · Novartis ...

Novartis AIN457 (secukinumab) showed significant symptom ...

EAST HANOVER, N.J. · "Ankylosing spondylitis is a debilitating condition that severely impacts patients' mobility, ability to work, and overall ...

Obstacles to Early Diagnosis and Treatment of Hidradenitis ...

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can progress to significant tunnels and scars that affect ...